Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions. As the 2026 ASCO Genitourinary (GU) Cancers ...

Zovegalisib (RLY-2608) is the first pan-mutant-selective PI3Kα inhibitor, binding a novel allosteric site distinct from ...

By sequencing the genomes of nearly 500 domestic cats with cancer, researchers found common genetic signatures between cats ...

Bella Grambau has been told she is the only person in Australia and one of only a handful of people in the world with a rare ...

The tumor suppressor gene PTEN plays an important role in many cancer types. Mechanism of PTEN inactivation includes gene mutations and deletions. In this large multi-center study, we analyzed the ...

Prostate cancer ranges from indolent to rapidly progressive. An elevated cell proliferation index portends poor outcomes, yet the molecular alterations essential for increased cell proliferation ...

Mn 2+ assembles with PTEN mRNA through weak forces rather than electrostatic interactions, facilitating reversible and efficient cellular mRNA release with a rational absolute binding free energies ...

This valuable study provides insights into the role of Pten mutations in SHH-medulloblastoma, by using mouse models to resolve the effects of heterozygous vs homozygous mutations on proliferation and ...

The share price of Patterson-UTI Energy, Inc. (NASDAQ:PTEN) surged by 20.33% between October 17 and October 24, 2025, putting it among the Energy Stocks that Gained the Most This Week. Patterson-UTI ...

ABSTRACT: Objective: Nedd4-1 has been reported to be overexpressed in various human cancers. In this study, we investigated the role of Nedd4-1 in carcinogenesis and prognosis of cervical cancer.

$PTEN insiders have traded $PTEN stock on the open market 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales. Here’s a ...

Association between prostate radiation therapy and survival among patients with metastatic prostate cancer by extent of disease burden. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...